Abstract

Urothelial cancer staged as T1G3 presents urologist with challenges, because it has poor outcome if treated as superficial bladder tumor. Transurethral resection is the standard treatment for the non-muscle-invasive bladder tumor. However, high-grade T1 bladder tumor has potentially bad prognosis and transurethral resection is not adequate treatment option. The recurrence rate after transurethral resection is 50-80% and progression rate to muscle-invasive disease is 27-63%. The treatment of choice for patients with high grade T1 bladder tumor is a matter of controversy. Herein, we reviewed the literature and guidelines regarding the management of patients diagnosed with high-grade T1 urothelial cancer.